EXSCIENTIA
Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST).
A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Exscientia
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.
For more information visit us on www.exscientia.com or follow us on LinkedIn @ex-scientia and X @exscientiaAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828867760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)11.3.2025 12:00:00 CET | Press release
Intent that RoslinCT is to perform technology transfer and commercial manufacture of Omisirge® at RoslinCT’s cell therapy manufacturing facility in Hopkinton, MA.Omisirge® is a commercialized mismatched unrelated cell therapy derived from the youngest donor source and banked for ease of infusion for patients with hematological malignancies. Ayrmid Pharma Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics and RoslinCT, a world leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced their intent to enter into a strategic partnership for the production of Omisirge, a commercial product for the treatment of hematologic malignancies commercialized in the US by Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd. It is the intent of the two companies to enter into an agreement whereby RoslinCT will perform technology transfer and commercial manufacture of Gamida Cell’s Omisirge. The cell-based product is a nicotinami
Kinaxis to Unveil the Next Phase of AI Innovation at Kinexions 202511.3.2025 12:00:00 CET | Press release
New agentic and generative AI capabilities will lower the barriers to entry and deliver critical business insights faster Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is set to unveil new artificial intelligence capabilities in its Maestro™ platform at Kinexions North America 2025, the company’s global innovation conference. These AI capabilities are designed to accelerate the value that AI can create in supply chains, helping companies navigate an increasingly volatile global trade environment - whether they are just beginning their AI journey or already leveraging advanced automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311610609/en/ The company will introduce AI agents that users can interact with to monitor, predict, and take action in real time — automating key tasks like inventory management and disruption mitigation. In addition, its agentic AI framework will enable compa
Verne Strikes 10MW Deal with Nebius to Further Expand Europe’s AI Capacity11.3.2025 11:00:00 CET | Press release
AI infrastructure company Nebius to deploy new NVIDIA GPU cluster at Verne’s 100% renewable-powered Icelandic campus Verne, the leading provider of sustainably powered HPC data centers across the Nordics, has today announced that Nebius, a leading global AI infrastructure provider, will be colocating a cluster of NVIDIA H200 GPUs at Verne’s data center campus in Iceland. This collaboration marks the largest single implementation in Verne Iceland’s history, with Nebius deploying a 10MW cluster. This installation is part of Nebius’ ambitious build-out of AI infrastructure across the US and Europe, supporting its mission to provide scalable, energy-efficient solutions for intensive AI workloads. As one of Europe’s leading providers of GPU capacity, Nebius selected Verne for its proven expertise, renewable energy-driven operations, and ability to meet precise technical and geographical requirements. Verne’s Icelandic facility, uniquely located on a former NATO base and powered entirely by
Allegro DVT Launches its First AI-Based Neural Video Processing IP11.3.2025 10:35:00 CET | Press release
Allegro DVT, a leader in video processing semiconductor solutions, is excited to announce the launch of its latest innovation, its first AI-based Neural Video Processing NVP300 IP. This groundbreaking product marks Allegro DVT’s commitment to embrace the AI revolution and push video quality to the next level, leveraging the advanced features and benefits of AI based video processing technologies. The new NVP300 semiconductor IP features an optimized hardware implementation to deliver real-time AI processing of 4K video within best-in-class silicon area and power budget suitable for embedded products. "We are thrilled to introduce our first AI-based Neural Video Processing IP to the market," said Nouar Hamze, CEO at Allegro DVT. "The NVP300 represents a significant advancement in video processing technology offering stunning subjective video quality improvements. It will greatly benefit our customers to power their next generation video compression solutions." The launch of the AI-based
Interactive Brokers Expands Global Reach with Ljubljana Stock Exchange Access11.3.2025 10:00:00 CET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced today that it has expanded its market offerings by adding access to the Ljubljana Stock Exchange. With this expansion, clients can trade Slovenian equities alongside products from over 160 other global exchanges, including stocks, options, futures, currencies, bonds, funds, and more, from a single unified platform. Enhancing Market Access for Global Investors Interactive Brokers provides access to over 160 markets across the Americas, Europe, and Asia, and adding the Ljubljana Stock Exchange further broadens the investment opportunities for our active traders and institutional investors. Clients can now include Slovenian stocks as part of their portfolio diversification strategies, complementing their European and global investments. "Interactive Brokers continues to expand its market coverage to meet the needs of global investors," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Add
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom